Hansa Biopharma Announces Confidential Submission of Draft Registration Statement to the SEC to allow for a potential Listing of ADSs in the United States

/in

Lund, Sweden, August 21, 2026. Hansa Biopharma AB (publ) (“Hansa” or the “Company”) today announces that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to a potential initial public offering of American Depositary Shares (“ADSs”), representing the Company’s ordinary shares, in the United […]

Read more

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

/in

ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration Based on PK data the therapeutic dose is expected to be ≤10mg once daily To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), […]

Read more

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

/in

Lund, Sweden, August 18, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA). “This first commercial living donor transplant patient in Australia represents an important milestone […]

Read more

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

/in

Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance Recent positive interim results showed safety and immunogenicity with early signals of activity Full week-100 results from Part 1 of VacSYn trial expected in H2 2026   Lausanne, Switzerland, August 11, 2026 – AC Immune SA (NASDAQ: ACIU), […]

Read more

Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine

/in

Clinical dosimetry results from Phase 1 studies of Radspherin® in ovarian and colorectal cancer demonstrate absorbed doses to normal organs well below values associated with toxicity risks The results are consistent with the favorable safety profile observed to date and support the further development of Radspherin® for treatment of peritoneal metastases Oslo, Norway, 11 August […]

Read more
© Optimum Strategic Communications.